Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
teriparatide 20 micrograms/day · 3 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| A | ACTIVE_COMPARATOR | teriparatide 20 micrograms/day subcutaneous |
| B | ACTIVE_COMPARATOR | salmon calcitonin 100 IU/day subcutaneous |
| Name | Type | Description |
|---|---|---|
| teriparatide 20 micrograms/day subcutaneous | DRUG | - |
| salmon calcitonin 100 IU/day subcutaneous | DRUG | - |
| calcitonin 100 IU/day subcutaneous | DRUG | - |
Inclusion Criteria: * Ambulatory, postmenopausal women aged 55-85 years (at least 3 years have elapsed after menopausal) are included at the time of entry into the trial. They have to be free of severe or chronically disabling conditions other than osteoporosis. * The patient should have a document...
Teriparatide 20 micrograms/day is used to treat osteoporosis in postmenopausal women. It is given as a subcutaneous injection and is studied in Phase 3 clinical trials for postmenopausal osteoporosis. The trials enrolled postmenopausal women aged 55 years and older.
Teriparatide 20 micrograms/day targets PTH1R, the parathyroid hormone 1 receptor, where it acts as an agonist. By activating this receptor, the drug stimulates bone formation. This mechanism underlies its use in treating postmenopausal osteoporosis.
Teriparatide 20 micrograms/day is developed by Eli Lilly and Company, which trades under the ticker LLY. Eli Lilly is the sponsor behind the clinical development program for this osteoporosis therapy.
Teriparatide 20 micrograms/day is in Phase 3 clinical development for postmenopausal osteoporosis. It is an investigational therapy, and the completed Phase 3 trials evaluated it in postmenopausal women with osteoporosis.
Teriparatide 20 micrograms/day has been studied in Phase 3 trials including NCT00543218 in Taiwan, NCT00543023 in China, and NCT00542984 in South Korea. All three trials are completed and enrolled postmenopausal women aged 55 years and older with osteoporosis.